RLYB
Rallybio Corporation
Price Chart
Latest Quote
$15.97
+0.05 (+0.31%)
Current Price
| Previous Close | $15.92 |
| Open | $15.91 |
| Day High | $16.07 |
| Day Low | $15.79 |
| Volume | 23,647 |
Stock Information
| Shares Outstanding | 5.80M |
| Total Debt | $154K |
| Cash Equivalents | $46.80M |
| Revenue | $858K |
| Net Income | $-7.82M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $92.63M |
| EPS (TTM) | $-1.36 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $37.97M |
| Sales | $858K |
| Income | $-7.82M |
| Book/sh | $9.50 |
| Cash/sh | $8.07 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 11.30 |
| Current Ratio | 12.92 |
| Debt/Eq | 0.31 |
Returns & Margins
| ROA | -33.82% |
| ROE | -14.98% |
| Operating Margin | -4119.34% |
Ownership
| Insider Ownership | 4.15% |
| Institutional Ownership | 107.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.96 |
| P/S | 107.96 |
| P/B | 1.68 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $15.70 |
| SMA50 | $12.90 |
| SMA200 | $7.63 |
| RSI | 70.03 |
| ATR | 0.7108 |
| Shares Float | 3.16M |
| Short Float | 11.96% |
| Short Ratio | 1.00 |
| Rel Volume | 0.42 |
Performance History
| Week | +0.31% |
| Month | +12.54% |
| Quarter | +75.69% |
| 6 Months | +159.93% |
| YTD | +182.36% |
| Year | +490.61% |
| 3 Years | -75.05% |
| 10 Years | -85.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $15.97 | 29,000 |
| 2026-06-17 | $15.92 | 36,500 |
| 2026-06-16 | $15.90 | 20,100 |
| 2026-06-15 | $15.90 | 138,600 |
| 2026-06-12 | $15.92 | 52,100 |
| 2026-06-11 | $15.92 | 25,500 |
| 2026-06-10 | $15.94 | 13,500 |
| 2026-06-09 | $15.91 | 24,200 |
| 2026-06-08 | $15.91 | 21,700 |
| 2026-06-05 | $15.95 | 35,100 |
| 2026-06-04 | $16.20 | 33,800 |
| 2026-06-03 | $16.07 | 54,500 |
| 2026-06-02 | $16.23 | 183,900 |
| 2026-06-01 | $16.87 | 451,900 |
| 2026-05-29 | $14.46 | 45,900 |
| 2026-05-28 | $14.52 | 21,300 |
| 2026-05-27 | $14.53 | 18,100 |
| 2026-05-26 | $14.70 | 36,300 |
| 2026-05-22 | $15.88 | 64,500 |
| 2026-05-21 | $15.38 | 68,600 |
| 2026-05-20 | $14.58 | 43,700 |
| 2026-05-19 | $14.19 | 90,300 |
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
đ° Latest News
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo â How Much Of The New Company Will Rallybio Shareholders Own?
Stocktwits âĸ 2026-06-01T16:26:29Z
RallyBio tries again for reverse merger, this time with Avenzo
BioPharma Dive âĸ 2026-06-01T15:03:00Z
Rallybio to acquire Candid Therapeutics
Pharmaceutical Technology âĸ 2026-03-03T12:29:42Z
Candid, in a reverse merger with RallyBio, to go public
BioPharma Dive âĸ 2026-03-02T11:05:43Z
Stock Splits Matter: Notable Splits in 2025 and Whatâs Happening in 2026
24/7 Wall St. âĸ 2026-02-04T15:05:07Z
Stock Splits Matter: Whatâs Coming Up This Month?
24/7 Wall St. âĸ 2026-02-04T15:05:07Z
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?
Simply Wall St. âĸ 2025-09-27T13:49:04Z
Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances
Insider Monkey âĸ 2025-09-21T13:26:02Z
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid
Insider Monkey âĸ 2025-08-17T22:16:33Z
Rallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024)
Simply Wall St. âĸ 2025-08-09T12:34:41Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $858,000 | $636,000 | $0 | $0 |
| Operating Revenue | $858,000 | $636,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $33,922,000 | $61,132,000 | $78,932,000 | $67,884,000 |
| Other Income Expense | $21,897,000 | $-1,495,000 | $-1,779,000 | $-733,000 |
| Other Non Operating Income Expenses | $22,771,000 | $744,000 | $262,000 | $342,000 |
| Net Non Operating Interest Income Expense | $2,189,000 | $4,216,000 | $6,147,000 | $1,963,000 |
| Operating Expense | $33,922,000 | $61,132,000 | $78,932,000 | $67,884,000 |
| General And Administrative Expense | $14,325,000 | $19,625,000 | $25,388,000 | $27,195,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Net Interest Income | $2,189,000 | $4,216,000 | $6,147,000 | $1,963,000 |
| Interest Income | $2,189,000 | $4,216,000 | $6,147,000 | $1,963,000 |
| Normalized Income | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Net Income From Continuing And Discontinued Operation | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Total Operating Income As Reported | $-33,064,000 | $-60,496,000 | $-78,932,000 | $-67,884,000 |
| Net Income Common Stockholders | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Net Income | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Net Income Including Noncontrolling Interests | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Net Income Continuous Operations | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Pretax Income | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Earnings From Equity Interest | $-874,000 | $-2,239,000 | $-2,041,000 | $-1,075,000 |
| Interest Income Non Operating | $2,189,000 | $4,216,000 | $6,147,000 | $1,963,000 |
| Operating Income | $-33,064,000 | $-60,496,000 | $-78,932,000 | $-67,884,000 |
| Earnings From Equity Interest Net Of Tax | - | - | - | $-1,075,000 |
| Per Share | ||||
| Diluted EPS | $-1.59 | $-10.64 | $-14.72 | $-16.72 |
| Basic EPS | $-1.59 | $-10.64 | $-14.72 | $-16.72 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-32,972,000 | $-60,365,000 | $-78,782,000 | $-67,717,000 |
| Reconciled Depreciation | $92,000 | $131,000 | $150,000 | $167,000 |
| EBITDA (Bullshit earnings) | $-32,972,000 | $-60,365,000 | $-78,782,000 | $-67,717,000 |
| EBIT | $-33,064,000 | $-60,496,000 | $-78,932,000 | $-67,884,000 |
| Diluted Average Shares | $5,629,370 | $5,443,103 | $5,055,923 | $3,977,663 |
| Basic Average Shares | $5,629,370 | $5,443,103 | $5,055,923 | $3,977,663 |
| Diluted NI Availto Com Stockholders | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Research And Development | $19,597,000 | $41,507,000 | $53,544,000 | $40,689,000 |
| Selling General And Administration | $14,325,000 | $19,625,000 | $25,388,000 | $27,195,000 |
| Other Gand A | $14,325,000 | $19,625,000 | $25,388,000 | $27,195,000 |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $57,956,000 | $61,654,000 | $106,184,000 | $169,317,000 |
| Total Assets | $62,261,000 | $68,108,000 | $115,620,000 | $180,435,000 |
| Total Non Current Assets | $1,008,000 | $267,000 | $831,000 | $939,000 |
| Other Non Current Assets | $810,000 | - | - | - |
| Current Assets | $61,253,000 | $67,841,000 | $114,789,000 | $179,496,000 |
| Other Current Assets | $2,517,000 | $995,000 | $2,054,000 | $1,050,000 |
| Prepaid Assets | $4,000,000 | $1,335,000 | $2,806,000 | $9,452,000 |
| Cash Cash Equivalents And Short Term Investments | $54,736,000 | $65,511,000 | $109,929,000 | $168,994,000 |
| Cash And Cash Equivalents | $31,374,000 | $13,903,000 | $24,494,000 | $56,958,000 |
| Debt | ||||
| Total Debt | $176,000 | $154,000 | $392,000 | $555,000 |
| Long Term Debt And Capital Lease Obligation | $82,000 | $0 | $173,000 | $374,000 |
| Current Debt And Capital Lease Obligation | $94,000 | $154,000 | $219,000 | $181,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,305,000 | $6,454,000 | $9,436,000 | $11,118,000 |
| Total Non Current Liabilities Net Minority Interest | $82,000 | $212,000 | $173,000 | $374,000 |
| Non Current Deferred Liabilities | $0 | $212,000 | $0 | - |
| Current Liabilities | $4,223,000 | $6,242,000 | $9,263,000 | $10,744,000 |
| Current Deferred Liabilities | $212,000 | $848,000 | $0 | - |
| Payables And Accrued Expenses | $1,583,000 | $2,145,000 | $5,878,000 | $5,860,000 |
| Payables | $126,000 | $278,000 | $976,000 | $1,114,000 |
| Accounts Payable | $126,000 | $278,000 | $976,000 | $1,114,000 |
| Equity | ||||
| Common Stock Equity | $57,956,000 | $61,654,000 | $106,184,000 | $169,317,000 |
| Total Equity Gross Minority Interest | $57,956,000 | $61,654,000 | $106,184,000 | $169,317,000 |
| Stockholders Equity | $57,956,000 | $61,654,000 | $106,184,000 | $169,317,000 |
| Gains Losses Not Affecting Retained Earnings | $18,000 | $68,000 | $15,000 | $-214,000 |
| Other Equity Adjustments | $18,000 | $68,000 | $15,000 | $-214,000 |
| Retained Earnings | $-301,998,000 | $-293,020,000 | $-235,245,000 | $-160,681,000 |
| Long Term Equity Investment | - | $0 | $239,000 | $30,000 |
| Other | ||||
| Ordinary Shares Number | $5,283,321 | $5,188,770 | $4,728,695 | $4,729,671 |
| Share Issued | $5,283,321 | $5,188,770 | $4,728,695 | $4,729,671 |
| Tangible Book Value | $57,956,000 | $61,654,000 | $106,184,000 | $169,317,000 |
| Invested Capital | $57,956,000 | $61,654,000 | $106,184,000 | $169,317,000 |
| Working Capital | $57,030,000 | $61,599,000 | $105,526,000 | $168,752,000 |
| Capital Lease Obligations | $176,000 | $154,000 | $392,000 | $555,000 |
| Total Capitalization | $57,956,000 | $61,654,000 | $106,184,000 | $169,317,000 |
| Additional Paid In Capital | $359,932,000 | $354,602,000 | $341,410,000 | $330,208,000 |
| Capital Stock | $4,000 | $4,000 | $4,000 | $4,000 |
| Common Stock | $4,000 | $4,000 | $4,000 | $4,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $0 | $212,000 | $0 | - |
| Long Term Capital Lease Obligation | $82,000 | $0 | $173,000 | $374,000 |
| Current Deferred Revenue | $212,000 | $848,000 | $0 | - |
| Current Capital Lease Obligation | $94,000 | $154,000 | $219,000 | $181,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,334,000 | $3,095,000 | $3,166,000 | $4,703,000 |
| Current Accrued Expenses | $1,457,000 | $1,867,000 | $4,902,000 | $4,746,000 |
| Net PPE | $198,000 | $267,000 | $592,000 | $909,000 |
| Accumulated Depreciation | $-480,000 | $-654,000 | $-523,000 | $-373,000 |
| Gross PPE | $678,000 | $921,000 | $1,115,000 | $1,282,000 |
| Leases | $147,000 | $338,000 | $338,000 | $338,000 |
| Machinery Furniture Equipment | $356,000 | $431,000 | $431,000 | $420,000 |
| Buildings And Improvements | $175,000 | $152,000 | $346,000 | $524,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $23,362,000 | $51,608,000 | $85,435,000 | $112,036,000 |
| Investments And Advances | - | $0 | $239,000 | $30,000 |
| Investmentsin Joint Venturesat Cost | - | $0 | $239,000 | $30,000 |
| Non Current Accrued Expenses | - | - | - | $0 |
| Construction In Progress | - | - | - | $0 |
| Other Properties | - | - | - | $524,000 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-29,813,000 | $-49,282,000 | $-60,277,000 | $-57,338,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-29,813,000 | $-49,282,000 | $-60,265,000 | $-57,284,000 |
| Cash Flow From Continuing Operating Activities | $-29,813,000 | $-49,282,000 | $-60,265,000 | $-57,284,000 |
| Operating Gains Losses | $-21,476,000 | $2,239,000 | $2,041,000 | $1,075,000 |
| Investing Activities | ||||
| Investing Cash Flow | $47,268,000 | $33,492,000 | $27,658,000 | $-112,170,000 |
| Cash Flow From Continuing Investing Activities | $47,268,000 | $33,492,000 | $27,658,000 | $-112,170,000 |
| Capital Expenditure | - | - | $-12,000 | $-54,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $5,405,000 | $0 | $51,533,000 |
| Financing Cash Flow | $16,000 | $5,199,000 | $143,000 | $51,078,000 |
| Cash Flow From Continuing Financing Activities | $16,000 | $5,199,000 | $143,000 | $51,078,000 |
| Net Common Stock Issuance | $0 | $5,405,000 | $0 | $51,533,000 |
| Common Stock Issuance | $0 | $5,405,000 | $0 | $51,533,000 |
| Net Other Financing Charges | - | $-268,000 | $-139,000 | $-693,000 |
| Other | ||||
| End Cash Position | $31,374,000 | $13,903,000 | $24,494,000 | $56,958,000 |
| Beginning Cash Position | $13,903,000 | $24,494,000 | $56,958,000 | $175,334,000 |
| Changes In Cash | $17,471,000 | $-10,591,000 | $-32,464,000 | $-118,376,000 |
| Proceeds From Stock Option Exercised | $16,000 | $62,000 | $282,000 | $238,000 |
| Net Investment Purchase And Sale | $28,768,000 | $35,492,000 | $29,920,000 | $-111,816,000 |
| Sale Of Investment | $46,465,000 | $84,425,000 | $138,334,000 | $89,500,000 |
| Purchase Of Investment | $-17,697,000 | $-48,933,000 | $-108,414,000 | $-201,316,000 |
| Net Business Purchase And Sale | $18,500,000 | $-2,000,000 | $-2,250,000 | $-300,000 |
| Sale Of Business | $20,000,000 | $0 | - | - |
| Purchase Of Business | $-1,500,000 | $-2,000,000 | $-2,250,000 | $-300,000 |
| Change In Working Capital | $-4,192,000 | $-258,000 | $4,277,000 | $-936,000 |
| Change In Other Working Capital | $-848,000 | $1,060,000 | - | - |
| Change In Payables And Accrued Expense | $-1,301,000 | $-4,042,000 | $-1,542,000 | $3,709,000 |
| Change In Accrued Expense | $-1,149,000 | $-3,344,000 | $-1,443,000 | $3,222,000 |
| Change In Payable | $-152,000 | $-698,000 | $-99,000 | $487,000 |
| Change In Account Payable | $-152,000 | $-698,000 | $-99,000 | $487,000 |
| Change In Prepaid Assets | $-2,043,000 | $2,724,000 | $5,819,000 | $-4,645,000 |
| Other Non Cash Items | $-573,000 | $-1,612,000 | $-3,089,000 | $-435,000 |
| Stock Based Compensation | $5,314,000 | $7,993,000 | $10,920,000 | $9,499,000 |
| Depreciation Amortization Depletion | $92,000 | $131,000 | $150,000 | $167,000 |
| Depreciation And Amortization | $92,000 | $131,000 | $150,000 | $167,000 |
| Earnings Losses From Equity Investments | $874,000 | $2,239,000 | $2,041,000 | $1,075,000 |
| Gain Loss On Sale Of Business | $-22,350,000 | $0 | - | - |
| Net Income From Continuing Operations | $-8,978,000 | $-57,775,000 | $-74,564,000 | $-66,654,000 |
| Net PPE Purchase And Sale | - | $0 | $-12,000 | $-54,000 |
| Purchase Of PPE | - | $0 | $-12,000 | $-54,000 |
Fetched: 2026-06-17